Superworth

Karyopharm Therapeutics EPS KPTI

Diluted earnings per share by quarter and over the last twelve months, from 2012.

Last 12 months, to Jun 30, 2026
−$13.09
Latest quarter, Q2 FY26
−$2.32
Fiscal year 2025
−$16.62

Karyopharm Therapeutics' earnings per share was −$13.09 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$2.32.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$16.62n/a
FY2024−$15.34n/a
FY2023−$18.75n/a
FY2022−$30.45n/a
FY2021−$24.90n/a
FY2020−$40.95n/a
FY2019−$48.45n/a
FY2018−$46.95n/a
FY2017−$42.00n/a
FY2016−$43.95n/a
FY2015−$49.80n/a
FY2014−$36.15n/a
FY2013−$146.40n/a
FY2012−$136.95n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$2.32n/a−$13.09
Q1 FY26−$1.24n/a−$15.09
Q4 FY25−$5.71n/a−$16.62
Q3 FY25−$3.82n/a−$14.58
Q2 FY25−$4.32n/a−$14.61
Q1 FY25−$2.77n/a−$13.26
Q4 FY24−$3.67n/a−$15.34
Q3 FY24−$3.85n/a−$17.07
Q2 FY24−$2.97n/a−$17.72
Q1 FY24−$4.85n/a−$19.10
Q4 FY23−$5.40n/a−$18.75
Q3 FY23−$4.50n/a−$19.80

Against its peers

Companies in Drug Manufacturers - General nearest Karyopharm Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
KPTIKaryopharm Therapeutics−$13.09
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Karyopharm Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.